NKTR Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Phase III InitiationMoving REZPEG into global registrational ZENITH AD trials represents a durable clinical de-risking step: it transitions the program from proof-of-concept to confirmatory studies, solidifying regulatory paths and enabling a clear commercialization timeline that will matter across the 2–6 month horizon and beyond.
Robust Phase IIb EfficacyDurable, deepening Phase IIb results (EASI-100 increases, sustained EASI-75/90 and itch improvement) strengthen the product’s clinical profile and regulatory argument. Such sustained efficacy supports label differentiation and physician adoption potential, affecting mid-term commercial viability and payer discussions.
Fortified Balance Sheet And RunwayA >$1B pro forma cash position and explicit runway into Q3 2028 materially reduces near-term financing pressure and allows the company to fund multiple Phase III programs and manufacturing scale-up without immediate dilution, preserving strategic optionality over the medium term.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow (~-$204M TTM) means the company will remain reliant on financing or large royalties to fund development. This ongoing burn creates structural funding risk and could force dilutive raises or program prioritization over the next several quarters.
Very Large Operating And Net LossesDeep negative margins driven by high R&D and operating costs indicate the business is far from break-even. Persistent large losses constrain returns and increase dependence on capital markets or partners, which is a durable constraint on shareholder value creation until commercialization occurs.
Execution & Regulatory Risks For Global Phase IIIsLarge, global Phase III programs create execution risk: site activation, CRO management, regional regulatory alignment and enrollment timing can materially delay readouts or increase costs. These operational challenges are structural for multinational registrational trials and affect timelines and capital needs over months.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is CHF1.91B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -$1.486 earnings per share for the quarter, missing the consensus estimate of -$1.292 by -$0.194.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -1.61.
How many shares outstanding does Nektar Therapeutics have?
Currently, no data Available
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.486 in its last earnings report, missing expectations of -$1.292. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in CH:NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF125.87 (― Downside)
CHF125.87 (― Downside)
Insider Transactions
Sold Shares
Worth CHF34.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
183.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Stock 12 Month Forecast
Average Price Target
$125.87
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―